15:03:15

GB0305163

JC13 Rec'd PCT/PTO

46

1	Claims	·
2		a la la al manada de la ala
3	1.	The use of (i) a naked binding member which
4		binds to both SCR1 and SCR2 of CD55 or (ii)
5		a nucleic acid encoding said binding member
6		in the preparation of a medicament for the
7		enhancement of complement deposition on a
8		tissue, wherein the naked binding member is
9		not bound to any agent having anti-tumour
10		properties.
11		and the state of t
12	2.	The use of (i) a naked binding member which
13		binds to both SCR1 and SCR2 of CD55 or (ii)
14		a nucleic acid encoding said binding member
15		in the preparation of a medicament for
16	,	treating cancer, wherein the naked binding
17		member is not bound to any agent having
18		anti-tumour properties.
19		
20	3.	The use according to claim 2 wherein the
21		cancer is one or more of colorectal, breast
22		, ovarian, cervical, gastric, lung, liver,
23		skin and myeloid (e.g. bone marrow) cancer.
24		
25	4.	The use according to any one of the
26		preceding claims wherein the binding member
27		is an antibody or a fragment thereof.
28		
29	5.	The use according to any one of the
30		preceding claims wherein the binding member
31		binds to amino acids 83-93and SCR2 amino
32		acids 101-112 and amino acids 145-157 of the

47

		- -
1		sequences shown in Figure 1b.
2		
3	6.	The use according to any one of the
4		preceding claims wherein the binding member
5		comprises one or more of the CDRs of the
6		antibody, or a fragment thereof, produced by
7		the cell line deposited at ATCC under
8		accession number HB9173.
9		
10	7.	The use according to any one of the
11		preceding claims wherein the binding member
12		is the antibody 791T/36 produced by the
13		hybridoma cell deposited at ATCC under
14	•	accession number HB9173.
15		
16	8.	The use according to any one of claims 1 to
17		7 wherein the binding member comprises at
18		least one human constant region.
19		·
20	9.	A naked binding member which binds to both
21		SCR1 and SCR2 for use in the treatment of
22		cancer.
23		and a second party
24	10.	
25		SCR1 and SCR2 of CD55, and an active agent
26		as a combined preparation for simultaneous,
27		separate or sequential use in the treatment
28		of cancer, wherein said active agent is a
29		chemotherapeutic agent, a pain relief agent
30		or an anti-emetic.

1	11.	The combined preparation according to claim
2		10, wherein said active agent is a
3		Doxorubicin, taxol, 5-Fluorouracil,
4		Irinotecan or Cisplatin.
5		•
6	12.	The combined preparation according to claim
7		10 wherein said active agent is an antibody.
8		
9 ·	13.	The combined preparation according to claim
10		13 wherein said active agent is an anti-CD20
11		antibody; an anti-VEGF antibody; an anti-
12		CD171A antibody; an anti-CEA anti-idiotypic
13		mAb; an anti-HMFG anti-idiotypic mAb; an
14		anti-EGFR antibody, or an anti-HER2 antibody
15		e.g. Herceptin, Genentech (South San
16		Francisco, CA, USA).
17		
18	14.	The naked binding member according to any
19		one of claims 9 to 10, or the combined
20		preparation according to any one of claims
21		11 to 13 wherein the naked binding member is
22		as defined in any one of claims 1 to 8.
23		
24	15.	A pharmaceutical composition for the
25		treatment of cancer, wherein the composition
26		comprises a naked binding member that binds
27		to both SCR1 and SCR2 of CD55 and a
28		pharmaceutically acceptable excipient,
29		diluent or carrier.
30		
31	16.	The pharmaceutical composition according to
20		claim 15 wherein the maked binding member

	•	
1		is as defined in any one of claims 1 to 8.
2		
3	17.	A method of neutralising the complement
4		activation inhibition activity of CD55,
5		comprising administration of a naked binding
6		member which specifically binds to SCR1 and
7		SCR2 of CD55.
8		
9	18.	A method of enhancing complement deposition
10		comprising administration of a naked binding
-		member which specifically binds to SCR1 and
11		SCR2 of CD55.
12		SCRZ OI CD33.
13		
14	19.	A method of treating cancer comprising
15		administration of a therapeutically
16		effective amount of a naked binding member
17		which specifically binds to SCR1 and SCR2 of
18		CD55 to a mammal in need thereof.
19		A method according to any one of claims 17
20	20.	
21		to 19 wherein the naked binding member is a
22		defined in any one of claims 1 to 8.
23		·
24		